This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.
Male or female patients aged 18-75 years;
Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery;
ECOG physical status score is 0-1;
Child-Pugh score is 5-6 points (Level A);
Patient can't provide blood samples for ctDNA testing;
Patient with two or more types of tumors at the same time;
Non-primary liver lesions;
Pregnant or lactating women;
Patient with hepatocellular carcinoma who can undergo radical surgical resection
Cohort
Prospective
circulating tumor DNA
Diagnostic testblood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
2-year recurrence-free survival rate
percentage of recurrence-free survival 2 years after surgery
Correlation between ctDNA-MRD status dynamic changes and relapse
Correlation between ctDNA-MRD status dynamic changes and relapse
Click on the lead sponsor to view all of their trials.
